Context

Medigene is a global leader in T Cell immunology.

Growing clinical pipeline in multiple indications and strong collaborations.

High-throughput platform for antigen and TCR discovery.

Listed on the Frankfurt Stock Exchange (Deutsche Börse) with a market cap of EUR330 million.

Fundraising to expand the company's ongoing clinical program with its T-cell receptor modified T cells (TCR-T) and to progress its pipeline of potential TCR-T candidates for future clinical development.

About Medigene

Medigene AG (FSE: MDG1, ISIN DE000A1X3W00, Prime Standard, TecDAX) is a publicly listed biotechnology company headquartered in Martinsried near Munich, Germany. The company is developing highly innovative immunotherapies to target various forms and stages of cancer. Medigene concentrates on the development of personalized T cell-based therapies, with associated projects currently in pre-clinical and clinical development.

Discover Medigene

Falk Müller-Veerse

Investment Banking

Pierre Kiecolt-Wahl

Investment Banking

Jean de Pracomtal

Investment Banking

Pierre Sertour

Equity Capital Markets

Pierre Sertour photo

Hervé Ronin

Investment Banking

Dr. Nicholas Hanser

Investment Banking

Dr. Mickael Dubourd

Investment Banking

Deal Team

Should you want to know more about this transaction, you can contact one of the team members above

Privacy Preference Center